Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02440685 · FLOW

Participant flow

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors · Source last updated 2023-06-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    ASN002 Dose 10 mg BID
    id
    FG000
    title
    10 mg BID
  2. description
    ASN002 20 mg BID
    id
    FG001
    title
    20 mg BID
  3. description
    ASN002 30 mg BID
    id
    FG002
    title
    30 mg BID
  4. description
    ASN002 40 mg BID
    id
    FG003
    title
    40 mg BID
  5. description
    ASN002 50 mg BID
    id
    FG004
    title
    50 mg BID
  6. description
    ASN002 75 mg BID
    id
    FG005
    title
    75 mg BID
  7. description
    ASN002 100 mg BID
    id
    FG006
    title
    100 mg BID
  8. description
    ASN002 80 mg QD
    id
    FG007
    title
    80 mg QD
  9. description
    ASN002 120 mg QD
    id
    FG008
    title
    120 mg QD
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        4
      5. group Id
        FG004
        num Subjects
        7
      6. group Id
        FG005
        num Subjects
        15
      7. group Id
        FG006
        num Subjects
        5
      8. group Id
        FG007
        num Subjects
        7
      9. group Id
        FG008
        num Subjects
        3
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        4
      5. group Id
        FG004
        num Subjects
        7
      6. group Id
        FG005
        num Subjects
        15
      7. group Id
        FG006
        num Subjects
        5
      8. group Id
        FG007
        num Subjects
        7
      9. group Id
        FG008
        num Subjects
        3
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    ASN002 Dose 10 mg BID
    id
    FG000
    title
    10 mg BID
  2. description
    ASN002 20 mg BID
    id
    FG001
    title
    20 mg BID
  3. description
    ASN002 30 mg BID
    id
    FG002
    title
    30 mg BID
  4. description
    ASN002 40 mg BID
    id
    FG003
    title
    40 mg BID
  5. description
    ASN002 50 mg BID
    id
    FG004
    title
    50 mg BID
  6. description
    ASN002 75 mg BID
    id
    FG005
    title
    75 mg BID
  7. description
    ASN002 100 mg BID
    id
    FG006
    title
    100 mg BID
  8. description
    ASN002 80 mg QD
    id
    FG007
    title
    80 mg QD
  9. description
    ASN002 120 mg QD
    id
    FG008
    title
    120 mg QD
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        4
      5. group Id
        FG004
        num Subjects
        7
      6. group Id
        FG005
        num Subjects
        15
      7. group Id
        FG006
        num Subjects
        5
      8. group Id
        FG007
        num Subjects
        7
      9. group Id
        FG008
        num Subjects
        3
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        4
      5. group Id
        FG004
        num Subjects
        7
      6. group Id
        FG005
        num Subjects
        15
      7. group Id
        FG006
        num Subjects
        5
      8. group Id
        FG007
        num Subjects
        7
      9. group Id
        FG008
        num Subjects
        3
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice